240 results about "Inflammatory cell" patented technology

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention discloses a grape seed source anti-inflammatory peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is selected from any one of WGF, SHFGF, EGPFF, WAPR, SFYRAF, HFAFL, PGRF or FDSF. A BPS-induced RAW 264.7 mouse mononuclear macrophage inflammation model is established, and the eight synthetic peptides are found to significantly reduce the content level of NO in inflammatory cells and have an inhibition effect on secretion of inflammatory factors TNF-alpha and IL-6. A qRT-PCR (quantitative reverse transcription-polymerase chain reaction) experiment shows that the synthetic peptide can inhibit expression of mRNA (messenger Ribonucleic Acid) of p65, Tnf alpha, Il6, Il1b and Nos2, and can play an anti-inflammatory role by regulating and controlling an NF-kappa B signal channel. According to the method, the high-activity anti-inflammatory peptide is screened from the wine brewing byproduct grape seeds for the first time, and green and high-value utilization of the grape processing byproduct is realized.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine compound for reducing recurrence of chronic nasosinusitis and a preparation method of the traditional Chinese medicine compound, and the traditional Chinese medicine compound is prepared from, by weight, 14-16 g of radix astragali, 8-10 g of fried radix scutellariae, 8-10 g of radix angelicae, 5-7 g of fructus xanthii, 5-7 g of flos magnoliae, 14-16 g of flos chrysanthemi indici, 11-13 g of fried fructus gardeniae, 5-7 g of radix angelicae sinensis, 5-7 g of flos carthami and 8-10 g of herba menthae. The traditional Chinese medicine composition can significantly improve clinical symptoms of patients with chronic nasosinusitis and reduce the recurrence rate, is good in safety, and does not find abnormal symptoms in clinical use. Meanwhile, the preparation process is simple to operate and suitable for industrial mass production. The raw medicinal materials selected by the traditional Chinese medicine composition are synergistic and complementary in nature and effect, inherit the holism concept of traditional Chinese medicine, emphasize that the traditional Chinese medicine composition emphasizes whole body treatment, plays a role together and inhibits infiltration of inflammatory cells while treating local parts, has small toxic and side effects, fully plays the advantages of treating chronic sinusitis and preventing relapse of the traditional Chinese medicine, relieves the pain of patients, and has a remarkable curative effect on treating chronic sinusitis. The life quality of patients is improved and the recurrence probability is reduced.

The invention relates to the technical field of hyaluronic acid derivatives and nano drug delivery systems, in particular to a lipoic acid grafted hyaluronic acid derivative, a preparation method and application, and provides a lipoic acid grafted hyaluronic acid derivative with a structure that lipoic acid is grafted with hyaluronic acid through a thioketal bond. A lipoic acid grafted hyaluronic acid derivative loaded IAA drug delivery system is constructed, can be gathered at a colitis disease part through intravenous injection, and is actively absorbed by cells by virtue of the affinity effect of hyaluronic acid in a lipoic acid grafted hyaluronic acid derivative structure on CD44 receptors on the surfaces of inflammatory cells; according to the present invention, with the application of the IAA in the cell, the responsive structure degradation occurs in the intracellular high oxidative stress environment, and the IAA is delivered into the cell in the positioning manner, such that the IAA inhibits the inflammation generation by activating the AhR and the downstream oxidative stress and inflammatory reaction related pathway so as to promote the mucous membrane repair, and the problem that the colitis treatment drug cannot accurately act on the focus in the prior art is solved.

A skin care composition includes a plurality of agents that include at least one retinol derivative that may comprise, for example, hydroxypinacolone retinoate, and at least one bark extract that may comprise, for example, Eperua falcata bark extract, the plurality of agents providing reduced retinol associated inflammation as compared with a composition that includes the at least one retinol and lacks the at least one bark extract. The plurality of agents may also include hydroxy acid, for example, comprising lactic acid. The composition may confer one or a combination of increased skin cell proliferation, improved cellular migration, improved cellular differentiation, an anti-inflammatory retinol genetic signature as demonstrated by via bulk-RNA sequencing of human keratinocytes and restores epidermal disruption and reduce IL-1A and IL-23 inflammatory cytokines in human ex-vivo skin models of chronic inflammation.

The invention discloses application of peimisine in preparation of an anti-fibrosis medicine, and belongs to the technical field of biological medicines. According to the application, mouse pulmonary interstitial fibrosis is induced through bleomycin, the treatment effect of peimine on pulmonary fibrosis is observed, and the influence of peimine on the pulmonary fibrosis process is explored. Results show that peimisine can reduce mouse lung index increase caused by bleomycin, improve damage of pulmonary alveolar structures of mice with pulmonary fibrosis, reduce aggregation of inflammatory cells, reduce serum fibrosis factors TGF-beta1 and inflammatory factors IL-2 of the mice with pulmonary fibrosis, and reduce the number of macrophages and neutrophils in BALF of the mice with pulmonary fibrosis. The peimisine has an obvious regulating effect on MRC-5 cell abnormal proliferation induced by TGF-beta1, can improve in-vivo pulmonary fibrosis induced by bleomycin by regulating the process of extracellular matrix and intercellular matrix, has an obvious treatment effect on mouse pulmonary fibrosis induced by bleomycin, is beneficial to development and utilization of peimisine, and has a good application prospect. And an effective method is provided for clinical treatment of pulmonary fibrosis.

The invention discloses a reverse-age anti-aging traditional Chinese medicine compound composition containing 2-oxoglutaric acid and a preparation method of the reverse-age anti-aging traditional Chinese medicine compound composition. The composition comprises ganoderma lucidum peptide, astragalus peptide, ginseng peptide, 2-oxoglutaric acid, gamma-aminobutyric acid, rehmannia, cistanche, Chinese yam, rhizoma polygonati, honeysuckle, dendrobium officinale and turmeric. The ganoderma lucidum peptide, the astragalus peptide, the ginseng peptide and other components cooperate with one another, so that free radicals can be removed, oxidation reaction can be inhibited, cell membranes can be stabilized, cell oxidative damage can be reduced, and senescence can be delayed. Components such as honeysuckle and turmeric can inhibit inflammation signal channels and reduce inflammatory factors, dendrobium officinale can regulate inflammatory cells, and astragalus membranaceus peptide and ginseng peptide can enhance immunity and reduce inflammatory hazards. In the cellular level, 2-oxoglutaric acid is used for supplying energy and regulating genes, and gamma-aminobutyric acid is used for improving sleep and promoting repair; on the whole, the multiple components can tonify vital qi, nourish viscera, improve qi and blood and improve skin and mental states. Through cooperation of multiple aspects, the disease risk is reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The invention belongs to the technical field of medicines, and particularly relates to application of muscone in preparation of a medicine for preventing or treating aortic dissection and the medicine. The invention relates to application of muscone in preparation of a medicine for preventing or treating aortic dissection. The medicine comprises one or more of the following effects: inhibiting aortic dilatation and dissection; aortic dilatation and dissection rupture are inhibited; the infiltration of macrophages in the aorta is inhibited; the apoptosis of aortic smooth muscle cells is inhibited; the effect of reducing inflammatory cytokines in the aorta is achieved; retrogressive lesions of the aortic medial membrane are inhibited; the degradation of the aortic dissection extracellular matrix is inhibited.

The three-dimensional propaganda and education model comprises a model main body, an identification assembly and a supporting base, the model main body is made of a transparent material, and an unqualified sputum specimen simulation unit (such as saliva and a polluted sputum specimen) and a qualified sputum specimen simulation unit (such as white viscous sputum, yellow viscous sputum and bloody sputum) are arranged in the model main body; each unit is of an independent cavity structure, and the sputum character is visually displayed by accurately controlling the color and viscosity and simulating particles (such as squamous epithelial cells or inflammatory cells); the identification assembly is used for clearly marking the type and the qualified standard through an identification board and a fluorescent coating; the supporting base provides stable placement. Through materialized comparison, the patient can quickly distinguish the sputum type, so that the retention quality is improved from the source, the percent of pass is remarkably improved, the nursing load is reduced, and the method has the advantages of intuition, standardization, high efficiency, safety and the like.

The present invention relates to a peptide for preventing or treating chronic obstructive pulmonary disease (COPD) and a use thereof. Specifically, the peptide prepared according to the present invention reduces the production of chemokines and inflammatory cytokines involved in pulmonary dysfunction in a COPD animal model, decreases the expression of genes causing excessive mucus production and the secretion of airway resistance factors, and exhibits the effect of inhibiting an increase in neutrophils, which are key cells related to COPD pathogenesis. Thus, the peptide can be effectively used as an active ingredient in a composition for preventing or treating COPD.

[Problem]The present invention demonstrates that, when added to the culture, DHMBA inhibits the proliferation of mouse inflammatory macrophage RAW264.7 cells, promotes their cell death, and reduces their cell number. It also demonstrates that DHMBA suppresses the increased production of inflammatory cytokines in RAW264.7 cells cultured with LPS, and in particular, DHMBA treatment suppresses osteoclast formation in RAW264.7 cells stimulated with LPS. Thus, the present invention provides a useful means of treating inflammatory diseases using DHMBA.[Solution]The present invention is characterized by having an anti-inflammatory effect by including 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient.

Disclosed are a myocarditis-targeted radionuclide molecular probe, a preparation method therefor, and an application thereof. The myocarditis-targeted radionuclide molecular probe includes a DPP4 inhibitor, a bifunctional chelator covalently bonded to an amino group of the DPP4 inhibitor, and a metallic radionuclide coordinately bonded to the bifunctional chelator. The myocarditis-targeted radionuclide molecular probe provided by the present disclosure exhibits high specificity and good targeting capability, and demonstrates significant uptake in myocardial inflammatory cells, and low uptake in non-target tissues. Characterized by high resolution and sensitivity of imaging, the myocarditis-targeted radionuclide molecular probe is applied for early diagnosis of cardiac inflammatory infiltration severity, therapeutic efficacy evaluation, prognosis assessment and the like, and has promising clinical and application prospects in the field of non-invasive nuclear medicine diagnosis and treatment as a myocarditis imaging agent.

The application discloses a kind of pentapeptide-based supramolecular assembly particles and its application as drug delivery carrier, belong to the field of biological assembly material.The TGCP of the present application, TGCP / nHA are prepared from TP5, HA and GA into carrier particles with drug loading performance and potential anti-inflammatory performance, it has spontaneous fluorescence performance, and can exist stably in neutral and alkaline environment, can be decomposed in acidic environment, can be loaded with small molecules with different solubility, and has certain programmed response performance at physiological and pathological pH.The present application is found through in-vitro experiment exploration that the carrier particles have good biocompatibility, and for in-vitro induced inflammatory cell experiment, it is found that TGCP and TGCP / nHA both have certain anti-inflammatory activity, can inhibit the expression of cell inflammatory factor IL-6, and play the role of inhibiting inflammation.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

A method of preparing cells for therapeutic use is provided in which a population of progenitor cells is cultured under cell culture conditions that promote progenitor cell differentiation, the cell culture conditions comprising the presence of G-CSF, GM-CSF, IL-3, and TNF; to produce a population of granulocytic cells. The produced granulocytic cells are useful in methods of treatment, including the treatment of cancer and infections, and the modulation of inflammatory cell responses.

Compositions comprising at least one nanoparticle containing a nucleoside RNA molecule encoding FOXP3 and an optional second agent are described herein. In some cases, the RNA molecule is circular and contains one or more IRES. Methods for treating or preventing inflammation are also described herein.

The application discloses a kind of self-assembly nanomaterial and its application in ROS clearance.The self-assembly nanomaterial of the application is denoted as TPP-FFYp-O, and its structural formula is shown as follows:TPP-FFYp-O of the application is specifically cut to generate TPP-FFY-O by alkaline phosphatase (ALP) overexpressed after entering inflammatory cell, TPP-FFY-O is enriched near mitochondrion by the targeting effect of TPP, and is self-assembled to form nanoparticle and stays in inflammatory cell by π-π stacking.Nanoparticle surface enrichment of a large number of TEMPO can convert superoxide radical anion (O2 ·‑ ) in mitochondrion into hydrogen peroxide (H2O2), and then decompose into oxygen and water, thereby significantly reducing the ROS level in inflammatory cell.This enzyme-controlled self-assembly nanoparticle improves the stability of TEMPO and the ability of ROS clearance, and has good application prospect.

A method for preparing cells for therapeutic use is provided, comprising culturing a population of progenitor cells under cell culture conditions that promote progenitor cell differentiation, including the presence of G-CSF, GM-CSF, IL-3, and TNF, to generate a population of granulocyte-producing cells. The generated granulocyte-producing cells may be useful in therapeutic methods, including the treatment of cancer and infections, and may also be useful in modulating inflammatory cell responses.

The invention discloses a preparation method of a coronary artery microcirculation disturbance animal model, and belongs to the technical field of biological medicine. According to the method, the stable mouse CMD model can be established by injecting 20-40 [mu] g / mL Calcimycin into the cardiac apex for the first time. Calcimycin is a calcium ion (Ca < 2 + >) carrier commonly used in a laboratory and can transport calcium ions outside cells into the cells, so that the concentration of the calcium ions in the cells is increased. Particularly, when 40 [mu] g / mL of Calcimycin is injected, the pathological severity of the Calcimycin is further aggravated, myocardial fiber arrangement is disordered, boundary is unclear, a large number of myocardial cells are necrotic and dissolved, cavitation is formed, vascular wall degeneration swelling is caused, inflammatory cell infiltration is caused, and thrombus is formed in microvessels.